Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG-009A in Moderate/Severe COVID-19 Pneumonia
NCT04561180Phase 2Withdrawn
- Sponsor
- Evergreen Therapeutics, Inc.
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of EG-009A in COVID-19 pneumonia (3 arms), sponsored by Evergreen Therapeutics, Inc. Primary endpoint: Proportion of patients alive and without respiratory failure at 28 days. Planned start Mar 2022; status: withdrawn.
02
Drugs
EG-009A
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04561180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561180.